The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Catalyst Trusteeship Ltd
THYROCARE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Catalyst Trusteeship Ltd, acting as Debenture Trustee, has disclosed the creation of a pledge on 3,23,23,232 equity shares of Thyrocare Technologies, representing 60.99% of the company's total share capital. The pledgor is Docon Technologies Private Limited, the promoter and holding company of Thyrocare, and the pledge is created to secure new debentures issued by API Holdings Ltd, the ultimate holding company. This is not an acquisition of voting shares but an encumbrance (pledge) created on September 17, 2025. The shares remain under encumbrance post-transaction at the same 60.99% level.
Over 60% of Thyrocare's shares now stand pledged by the promoter group to secure parent-level (API Holdings) borrowings, which raises governance and financial risk concerns for retail shareholders as any default at the holding company level could trigger invocation of the pledge and potential change in ownership.